drugset

drugset / Trial / NCT01308762

A Clinical Study, to Evaluate the Safety and Tolerability of Intradermal IMM-101 in Adult Melanoma Cancer Patients

NCT01308762 ↗

Phase 1 Completed 19 enrolled Immodulon Therapeutics Ltd HCA International Limited · collab Theradex · collab

NaSingle-groupSingle-blind

Summary

To evaluate the safety and tolerability of intradermal injections of IMM-101 (Heat-killed Mycobacterium obuense) in melanoma cancer patients.

Timeline

Start: 2010-03
Primary completion: 2010-09
Completion: 2010-09

Publications

Stebbing J, Dalgleish A, Gifford-Moore A, Martin A, Gleeson C, Wilson G, Brunet LR, Grange J, Mudan S. An intra-patient placebo-controlled phase I trial to evaluate the safety and tolerability of intradermal IMM-101 in melanoma. Ann Oncol. 2012 May;23(5):1314-1319. doi: 10.1093/annonc/mdr363. Epub 2011 Sep 19.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	IMM-101	Other / unclassified	0.1 mg	Other
Subject	IMM-101	Other / unclassified	0.5 mg	Other
Subject	IMM-101	Other / unclassified	1 mg	Other

Indications